Menu
Live
Market Overview
Live indices, gainers & losers
Market Pulse
AI-curated live updates
Market Movers
Top gainers & losers by cap
Market Signals
Value, momentum & analyst signals
Smart Money
Insider & congress trades
Hedge Funds
What 63 elite funds bought & sold
52-Week Highs
Stocks breaking out to new highs
52-Week Lows
Beaten-down stocks near support
High Beta
Stocks that move more than the market
Earnings Calendar
Upcoming earnings dates
Daily
Research
Invest
LIVE
Certara, Inc.
CERT
NASDAQ·Healthcare·Medical - Healthcare Information Services·Mkt cap $1.0B
$6.97
▲ +3.57%
View full research view
Our plain-language verdict, the thesis, risk factors, and what is changing about the business.
View research view52-Week Range
$4.45 - $13.88
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Down 41.4% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Proprietary biosimulation and mechanistic modeling technology
- Comprehensive end-to-end drug development solutions
- Strong customer relationships with top-20 pharmaceutical companies
- Skilled workforce of scientific and regulatory experts
Bear Case
1 risk
- Average volatility.
Growth
Turning profitable
Increased adoption of model-based drug development approaches
Value
Fairly valued vs Healthcare IT & Services peers
Momentum
Hot
+24.4% over 3m
Quality
Strong
Strong fundamentals
Dividend
None
No dividend
Smart-money signal
Who's buying CERT right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Aug 5, 2026
MAY 11, 2026
Reported EPS of $0.09 vs $0.11 consensus (-18.2% surprise). Revenue of $106.9M vs $106.1M expected (+0.7%).
EPS surprise · last 4Q
0 of 1 beats
Q2 26
-18.2%
Next: Aug 5, 2026
Revenue trend · last 8Q
—
—
—
+10%
+12%
+10%
+3%
+1%
Q2 24
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
$93.3M
$94.8M
$100.4M
$106.0M
$104.6M
$104.6M
$103.6M
$106.9M
Margins · last 8Q
Gross
—
Operating
—
Profit
-8.2%
Wall Street consensus
7 analysts · 29% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
29%
Hold
71%
Sell
0%
Median Price Target
$8.00
▲ +14.8% vs $6.97
Latest: BMO Capital · May 12, 2026
1 analyst covering